Fundraising FoxLumira Ventures — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Exact Imaging develops the ExactVu micro-ultrasound platform, a 29 MHz imaging system that lets urologists perform real-time targeted and systematic prostate biopsies within a standard workflow.
HardwareHealthtechMedical DevicesMarkham, CA
Harold Wodlinger(Director)inRandy AuCoin(President & CEO)inRob Sandler(Executive Officer)inJerrold Wen(Executive Officer)in
BoardWilliam Wortman(Director)Gaston Matthyssens(Director)
Board seatPeter van der Velden· per SEC Form D
Co-investorsiGan PartnersPMVVenture OntarioVesalius Biocapital Partners
HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients.
BiotechHardwareHealthtechMedical DevicesAnn Arbor, GB
Thomas Davison(Executive Officer, Director)inM. Christine Gibbons(Executive Officer, Director)inWen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Fred Lee(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsAlpha JWC VenturesAlpha Wave GlobalAmzak HealthArboretum VenturesClarevia VenturesEarly Stage Partners, LP+8 more
BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.
Digital HealthHealthtechMedical DevicesSeattle, US
Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)
Co-investorsAPERTURE Venture PartnersAphelion CapitalAscension VenturesRC CapitalRex Health VenturesSV Health Investors+2 more
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).
BiotechHealthtechMedical DevicesSouth San Francisco, US
John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)inRob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)
Co-investorsOUP (Osage University Partners)Vivo CapitalWellington ManagementRA CapitalRed Tree VentureSBI Investment
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.